{"id":"NCT02395016","sponsor":"Biotech Pharmaceutical Co., Ltd.","briefTitle":"A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer","officialTitle":"A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04","primaryCompletion":"2021-11","completion":"2021-11","firstPosted":"2015-03-20","resultsPosted":"2024-04-04","lastUpdate":"2024-04-04"},"enrollment":90,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pancreatic Cancer"],"interventions":[{"type":"DRUG","name":"nimotuzumab","otherNames":["Taixinsheng"]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Nimotuzumab and Gemcitabine","type":"EXPERIMENTAL"},{"label":"Placebo and Gemcitabine","type":"PLACEBO_COMPARATOR"}],"summary":"Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different indications. Nimotuzumab has been approved to treat squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal carcinoma in different countries.The clinical phase Ⅲ trial designed to assess overall survival（OS）of the combination of Nimotuzumab administered concurrently with Gemcitabine in patients with RAS wild type of locally advanced or metastatic pancreatic cancer","primaryOutcome":{"measure":"Overall Survival（OS）","timeFrame":"up to 3 years","effectByArm":[{"arm":"Nimotuzumab- Gemcitabine Group","deltaMin":10.9,"sd":null},{"arm":"Placebo-Gemcitabine Group","deltaMin":8.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":6},"locations":{"siteCount":25,"countries":["China"]},"refs":{"pmids":["37647576"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":45},"commonTop":["white blood cell count decreased","utrophil count decreased"]}}